| Identification | Back Directory | [Name]
Resolvin D2 | [CAS]
810668-37-2 | [Synonyms]
RvD2
IKFAUGXNBOBQDM-XFMPMKITSA-N
4,8,10,12,14,19-Docosahexaenoic acid, 7,16,17-trihydroxy-, (4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)- | [Molecular Formula]
C22H32O5 | [MDL Number]
MFCD18427928 | [MOL File]
810668-37-2.mol | [Molecular Weight]
376.49 |
| Chemical Properties | Back Directory | [Boiling point ]
609.2±55.0 °C(Predicted) | [density ]
1.101±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -80°C,protect from light | [solubility ]
DMF: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): .05 mg/ml | [form ]
Liquid | [pka]
4.58±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Description]
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; ) and docosahexaenoic acid (DHA; ). In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state. Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation. It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM. Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance. Analytical and biological comparisons of synthetic RvD2 with endogenously derived RvD2 have confirmed its identity as matching the natural product. | [Uses]
Resolvin D2 is a lipid mediator. | [Definition]
ChEBI: Resolvin D2 is a member of the class of resolvins that is (4Z,8E,10Z,12E,14E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 7, 16 and 17 (the 7S,16R,17S-stereoisomer). It has a role as a human xenobiotic metabolite, an anti-inflammatory agent, an estrogen receptor agonist, an anti-obesity agent and a rat metabolite. It is a resolvin, a triol, a secondary allylic alcohol and a hydroxy polyunsaturated fatty acid. It is a conjugate acid of a resolvin D2(1-). | [in vivo]
Resolvin D2 induces active resolution of inflammation with pulp-like tissue regeneration after root canal infection and thus maybe suitable for treating periapical lesions[1].
Resolvin D2 decreases leukocyte:endothelial interactions in vivo by endothelial-dependent nitric oxide production, and direct modulation of leukocyte adhesion receptor expression[2].
Peripheral administration of Resolvin D2 (10 ng; Intraplantar administration) potently inhibits inflammatory pain[3].
| Animal Model: | Adult CD1 mice (male, 8–10 weeks)[3] | | Dosage: | 10 ng | | Administration: | Intraplantar administration | | Result: | Inhibited inflammatory pain. |
| [References]
[1] MATTHEW SPITE. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis[J]. Nature, 2009, 461 7268: 1287-1291. DOI: 10.1038/nature08541 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|